

# Jecko Thachil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1061544/publications.pdf>

Version: 2024-02-01

141  
papers

8,855  
citations

100601

38  
h-index

51423

90  
g-index

141  
all docs

141  
docs citations

141  
times ranked

13887  
citing authors

#	ARTICLE	IF	CITATIONS
1	ISTH interim guidance on recognition and management of coagulopathy in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1023-1026.	1.9	1,513
2	Coagulation abnormalities and thrombosis in patients with COVID-19. <i>Lancet Haematology</i> , 2020, 7, e438-e440.	2.2	1,186
3	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865.	1.9	547
4	Coagulopathy in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2103-2109.	1.9	453
5	Coagulopathy of Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1358-1364.	0.4	412
6	The unique characteristics of COVID-19 coagulopathy. <i>Critical Care</i> , 2020, 24, 360.	2.5	366
7	The versatile heparin in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1020-1022.	1.9	343
8	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1989-1994.	1.9	325
9	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. <i>BMJ Open</i> , 2017, 7, e017046.	0.8	230
10	Effects of the COVID-19 pandemic on supply and use of blood for transfusion. <i>Lancet Haematology</i> , 2020, 7, e756-e764.	2.2	216
11	Vitamin B12 deficiency – A 21st century perspective. <i>Clinical Medicine</i> , 2015, 15, 145-150.	0.8	167
12	Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. <i>Blood Reviews</i> , 2009, 23, 167-176.	2.8	151
13	Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 452-463.	0.7	115
14	British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. <i>British Journal of Haematology</i> , 2018, 181, 54-67.	1.2	114
15	Anticoagulation in chronic kidney disease patients—the practical aspects. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 442-449.	1.4	104
16	Human CRP Defends against the Toxicity of Circulating Histones. <i>Journal of Immunology</i> , 2013, 191, 2495-2502.	0.4	102
17	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
18	Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1191-1199.	1.4	94

#	ARTICLE	IF	CITATIONS
19	Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 189, 1038-1043.	1.2	89
20	SARS-2 Coronavirus-associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 777-780.	1.5	85
21	How do we approach thrombocytopenia in critically ill patients?. <i>British Journal of Haematology</i> , 2017, 177, 27-38.	1.2	83
22	Proposal of the Definition for COVID-19-Associated Coagulopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 191.	1.0	83
23	A proposal for staging COVID-19 coagulopathy. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 731-736.	1.0	82
24	Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. <i>Critical Care</i> , 2019, 23, 280.	2.5	79
25	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	1.9	69
26	What do monitoring platelet counts in COVID-19 teach us?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2071-2072.	1.9	66
27	Supportive management strategies for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 896-904.	1.8	65
28	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 643-649.	1.3	60
29	Harmonisation of D-dimer — A call for action. <i>Thrombosis Research</i> , 2016, 137, 219-220.	0.8	56
30	Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 740-747.	1.9	56
31	COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women's Health. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3086-3098.	1.9	54
32	Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. <i>International Journal of Hematology</i> , 2016, 103, 253-261.	0.7	53
33	Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. <i>Critical Care</i> , 2016, 20, 287.	2.5	51
34	D-Dimer Testing: Laboratory Aspects and Current Issues. <i>Methods in Molecular Biology</i> , 2017, 1646, 91-104.	0.4	49
35	The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2408-2411.	1.9	49
36	Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 572-581.	1.5	47

#	ARTICLE	IF	CITATIONS
37	Potential diagnostic markers for disseminated intravascular coagulation of sepsis. <i>Blood Reviews</i> , 2016, 30, 149-155.	2.8	41
38	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. <i>Thrombosis Research</i> , 2019, 179, 11-14.	0.8	41
39	A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 439-445.	0.7	40
40	Disseminated intravascular coagulation – new pathophysiological concepts and impact on management. <i>Expert Review of Hematology</i> , 2016, 9, 803-814.	1.0	39
41	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 39-47.	1.9	39
42	Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1265-1268.	1.9	37
43	Hypoxia – An overlooked trigger for thrombosis in COVID-19 and other critically ill patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3109-3110.	1.9	37
44	DIC in Pregnancy – Pathophysiology, Clinical Characteristics, Diagnostic Scores, and Treatments. <i>Journal of Blood Medicine</i> , 2022, Volume 13, 21-44.	0.7	37
45	Antiplatelet therapy – a summary for the general physicians. <i>Clinical Medicine</i> , 2016, 16, 152-160.	0.8	36
46	All those D-dimers in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2075-2076.	1.9	34
47	Cerebral venous thrombosis – A primer for the haematologist. <i>Blood Reviews</i> , 2015, 29, 45-50.	2.8	32
48	Deep vein thrombosis. <i>Hematology</i> , 2014, 19, 309-310.	0.7	29
49	The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2015, 135, 897-901.	0.8	27
50	Thromboembolic events are not uncommon in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2010, 150, 496-497.	1.2	26
51	Disseminated Intravascular Coagulation. <i>Anesthesiology</i> , 2016, 125, 230-236.	1.3	25
52	DIC in obstetrics: Diagnostic score, highlights in management, and international registry – communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1562-1566.	1.9	25
53	The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory states. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1849-1852.	1.9	25
54	Laboratory haemostasis monitoring in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2058-2060.	1.9	25

#	ARTICLE	IF	CITATIONS
55	Granulocytic sarcoma – a rare presentation of a breast lump. <i>Annals of the Royal College of Surgeons of England</i> , 2007, 89, 7-9.	0.3	24
56	Current concepts in the management of disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2012, 129, S54-S59.	0.8	22
57	Management of disseminated intravascular coagulation: A survey of the International Society on Thrombosis and Haemostasis. <i>Thrombosis Research</i> , 2015, 136, 239-242.	0.8	21
58	Anemia – The overlooked factor in bleeding related to liver disease. <i>Journal of Hepatology</i> , 2011, 54, 593-594.	1.8	20
59	The Elusive Diagnosis of Disseminated Intravascular Coagulation: Does a Diagnosis of DIC Exist Anymore?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 100-107.	1.5	20
60	D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 39.	1.0	20
61	The use of fondaparinux in pregnancy. <i>British Journal of Haematology</i> , 2015, 168, 762-764.	1.2	19
62	Management of parturients with Factor XI deficiency – 10 year case series and review of literature. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 215, 85-92.	0.5	19
63	Type and dose of heparin in Covid-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2063-2064.	1.9	19
64	The problem of pulmonary embolism diagnosis in pregnancy. <i>British Journal of Haematology</i> , 2015, 170, 727-728.	1.2	17
65	DOACs and –newer–hemophilia therapies in COVID-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1795-1796.	1.9	17
66	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. <i>Acta Haematologica</i> , 2021, 144, 418-426.	0.7	17
67	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2016, 145, 46-50.	0.8	16
68	Recurrent venous thromboembolism while on anticoagulant therapy. <i>Blood Reviews</i> , 2012, 26, 175-181.	2.8	14
69	Management of bleeding and procedures in patients on antiplatelet therapy. <i>Blood Reviews</i> , 2020, 39, 100619.	2.8	14
70	Complete remission of refractory immune thrombocytopenia (<sc>ITP</sc>) with a short course of <sc>R</sc>omiplostim. <i>European Journal of Haematology</i> , 2013, 91, 376-377.	1.1	12
71	Portal vein thrombosis – a primer for the general physician. <i>Clinical Medicine</i> , 2017, 17, 212-219.	0.8	12
72	Nonovert disseminated intravascular coagulation (DIC) in pregnancy: a new scoring system for the identification of patients at risk for obstetrical hemorrhage requiring blood product transfusion. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 242-257.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	1.0	12
74	Lessons learnt from COVID-19 coagulopathy. EJHaem, 2021, 2, 577-584.	0.4	12
75	D-dimers "Normal" Levels versus Elevated Levels Due to a Range of Conditions, Including D-dimeritis, Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Seminars in Thrombosis and Hemostasis, 2022, 48, 672-679.	1.5	12
76	Platelets and infections in the resource-limited countries with a focus on malaria and viral haemorrhagic fevers. British Journal of Haematology, 2017, 177, 960-970.	1.2	11
77	Modified ISTH pregnancy-specific DIC score in parturients with liver rupture: population-based case series. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 2517-2523.	0.7	11
78	Differentiating biochemical from clinical heparin resistance in COVID-19. Journal of Thrombosis and Thrombolysis, 2020, 50, 1015-1016.	1.0	10
79	Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin. Journal of Thrombosis and Haemostasis, 2020, 18, 2424-2425.	1.9	10
80	Similarities and perspectives on the two "Cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 1161-1167.	1.9	10
81	COVID-19 (SARS-CoV-2) in Non-Airborne body fluids: A systematic review & Meta-analysis. Turkish Journal of Urology, 2021, 47, 87-97.	1.3	10
82	Chronic anticoagulation is not associated with a reduced risk of acute kidney injury in hospitalised Covid-19 patients. BMC Nephrology, 2021, 22, 224.	0.8	8
83	Heparin "Messias or Verschlimmbesserung?. Journal of Thrombosis and Haemostasis, 2021, 19, 2373-2382.	1.9	8
84	How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?. Blood Reviews, 2017, 31, 151-157.	2.8	6
85	Reintroduction of anticoagulant therapy after intracranial haemorrhage: If and when?. Blood Reviews, 2018, 32, 256-263.	2.8	6
86	Practical treatment guidance for cancer-associated thrombosis "Managing the challenging patient: A consensus statement. Critical Reviews in Oncology/Hematology, 2022, 171, 103599.	2.0	6
87	Extreme Thrombocytosis-An Unusual Presentation of Inflammatory Bowel Disease. Internal Medicine, 2008, 47, 1255-1257.	0.3	5
88	Alternate considerations for current concepts in ITP. Hematology, 2014, 19, 163-168.	0.7	5
89	Investigating easy bruising in an adult. BMJ: British Medical Journal, 2017, 356, j251.	2.4	5
90	The application of anticoagulant therapy to sepsis. Journal of Intensive Care, 2017, 5, 32.	1.3	5

#	ARTICLE	IF	CITATIONS
91	Managing sepsis-associated coagulopathy remains an enigma. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1586-1589.	1.9	5
92	Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?. <i>Intensive Care Medicine</i> , 2016, 42, 1193-1194.	3.9	4
93	The beneficial effect of acute phase increase in serum ferritin. <i>European Journal of Internal Medicine</i> , 2016, 35, e16-e17.	1.0	4
94	Ventilation perfusion scan or computed tomography pulmonary angiography for the detection of pulmonary embolism?. <i>European Journal of Internal Medicine</i> , 2016, 32, e26-e27.	1.0	4
95	Diagnosis of overt and non-overt disseminated intravascular coagulation: A survey among experts and a call for action from the ISTH. <i>Thrombosis Research</i> , 2017, 152, 74-76.	0.8	4
96	Mixing studies for abnormal coagulation screen – the current trend. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e54-e55.	1.4	4
97	The Comparison of the Protective Effects of $\hat{1}\pm$ - and $\hat{1}^2$ -Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro. <i>TH Open</i> , 2017, 01, e3-e10.	0.7	4
98	A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. <i>Journal of Neurology</i> , 2021, 268, 2390-2401.	1.8	4
99	Heparin induced thrombocytopenia with thrombosis: a two step process?. <i>Hematology</i> , 2008, 13, 181-182.	0.7	3
100	The possible role of reticulocytes in sickle cell disease associated thromboembolism. <i>Hematology</i> , 2008, 13, 68-70.	0.7	3
101	Thrombocytopenia in an adult. <i>BMJ, The</i> , 2013, 346, f3407-f3407.	3.0	3
102	Haemolysis secondary to intravenous immunoglobulins for ITP. <i>Hematology</i> , 2013, 18, 178-180.	0.7	3
103	Dispelling myths about coagulation abnormalities in internal medicine. <i>Clinical Medicine</i> , 2014, 14, 239-244.	0.8	3
104	The problem with incidental and chronic portal vein thrombosis. <i>European Journal of Internal Medicine</i> , 2017, 39, e29-e30.	1.0	3
105	Reply to ‘‘Errors in the diagnosis for DIC due to a statistical misunderstanding’’. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1792-1793.	1.9	3
106	Erythropoietin Corrects Thrombocytopenia. <i>American Journal of Medicine</i> , 2013, 126, e3-e4.	0.6	2
107	Steroids and Arteriovenous Thrombosis. <i>Chest</i> , 2013, 143, 1836.	0.4	2
108	You can bleed, you are on blood thinners!. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1379-1380.	1.9	2

#	ARTICLE	IF	CITATIONS
109	Thromboprophylaxis in COVID-19 – Rationale and considerations. <i>Advances in Biological Regulation</i> , 2021, 81, 100819.	1.4	2
110	A practical approach to thrombophilia testing. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 0.2	0.2	2
111	Anticoagulation in thrombocytopenic patients – time to rethink?. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	2
112	Nephrotic syndrome with spontaneous anticoagulant activity. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 624-626.	0.4	1
113	Phenotypic implications of a co-existent haemorrhagic and thrombotic genotype. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 232-234.	0.5	1
114	Why do thrombocytopenic patients bleed?. <i>Transfusion</i> , 2013, 53, 3280-3281.	0.8	1
115	Has deep vein thrombosis become a new epidemic?. <i>European Journal of Internal Medicine</i> , 2014, 25, e96-e97.	1.0	1
116	What is the evidence for platelet transfusion thresholds?. <i>European Journal of Internal Medicine</i> , 2014, 25, e37.	1.0	1
117	Relevance of clotting screen requests. <i>European Journal of Internal Medicine</i> , 2014, 25, e111-e112.	1.0	1
118	Myelofibrosis in ITP and with TPO-RA – time to rethink?. <i>Platelets</i> , 2020, 32, 1-2.	1.1	1
119	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter to the Editor by Dr Wada. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1507-1509.	1.9	1
120	Dual origins and dual roles for von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 308-309.	1.9	1
121	Similarities in coagulation for turophiles and clottologists. <i>British Journal of Haematology</i> , 2021, 193, e43-e44.	1.2	1
122	Are white blood cells white?. <i>British Journal of Haematology</i> , 2021, 193, e31-e32.	1.2	1
123	The relation between fibrinogen level, neutrophil activity and nucleosomes in the onset of disseminated intravascular coagulation in the critically ill. <i>Journal of Internal Medicine</i> , 2021, 290, 922-927.	2.7	1
124	Two Factor XI Concentrates Correct Impaired Thrombin Generation in Major FXI Deficiency but Are Not Equivalent in Their Effect. <i>Blood</i> , 2014, 124, 1519-1519.	0.6	1
125	The difficult distinction between haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 132-133.	1.4	0
126	A case of benign, multiple metastases. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 999-1000.	0.2	0



#	ARTICLE	IF	CITATIONS
127	Clotting Screen Requests in Pediatrics. Indian Journal of Pediatrics, 2012, 79, 1233-1235.	0.3	0
128	Thrombocytopenia and Thromboprophylaxis. Chest, 2013, 144, 1979.	0.4	0
129	Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC?. Intensive Care Medicine, 2017, 43, 152-153.	3.9	0
130	The authors reply. Critical Care Medicine, 2020, 48, e989-e990.	0.4	0
131	Could bloodletting have helped?. QJM - Monthly Journal of the Association of Physicians, 2021, , .	0.2	0
132	History of the word "œpurpura" and its current relevance. Journal of Thrombosis and Haemostasis, 2021, 19, 2318-2321.	1.9	0
133	D-dimers: a most misunderstood test. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-5.	0.2	0
134	Why do patients with DIC bleed?. Journal of Thrombosis and Haemostasis, 2021, 19, 2630-2631.	1.9	0
135	D-Dimer and thrombosis in COVID-19. Indian Journal of Vascular and Endovascular Surgery, 2021, 8, 6.	0.0	0
136	Contact Activation Inhibition and Platelet Rich Plasma Are Required in Order to Differentiate Bleeders from Non-Bleeders in FXI Deficiency Using the Thrombin Generation Assay. Blood, 2014, 124, 696-696.	0.6	0
137	Embolism "The journey from a calendar to the clot via the Lord's prayer. Journal of Thrombosis and Haemostasis, 2022, 20, 538-539.	1.9	0
138	Management of haemostatic complications of chimaeric antigen receptor T cell therapy. British Journal of Haematology, 2022, 197, 250-259.	1.2	0
139	Hemostasis in tweeters. Journal of Thrombosis and Haemostasis, 2022, 20, 272-273.	1.9	0
140	The problem with coagulopathy   . Journal of Thrombosis and Haemostasis, 0, , .	1.9	0
141	Exploring the epidemiology of disseminated intravascular coagulation: protocol for the DANish Disseminated Intravascular Coagulation (DANDIC) Cohort Study. BMJ Open, 2022, 12, e062623.	0.8	0